MAPK14 and colorectal carcinoma: On the other hand, the proposed co-upregulated kinases (CSNK2A1, CDK1, MAPK14, CDK4, GSK3B, AKT1, CDK2, among others) could be more realistic druggable targets and, therefore, yield a significant clinical benefit for CRC patients.